Congress Asset Management Co. Cuts Stake in Halozyme Therapeutics

Biopharmaceutical company Halozyme Therapeutics sees 9.4% decrease in shares held by investment firm

Mar. 24, 2026 at 8:38am

Got story updates? Submit your updates here. ›

Congress Asset Management Co. decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 9.4% in the fourth quarter, according to a filing with the Securities and Exchange Commission. The firm owned 1,302,180 shares of the biopharmaceutical company's stock after selling 134,353 shares during the quarter.

Why it matters

Halozyme Therapeutics is a prominent biopharmaceutical company focused on drug delivery technologies. Changes in major institutional investors' holdings can signal shifts in market sentiment and impact the stock price.

The details

Congress Asset Management Co. sold 134,353 shares of Halozyme Therapeutics in the fourth quarter, reducing its total stake to 1,302,180 shares. This represented a 9.4% decrease in the firm's position. Halozyme Therapeutics is a biopharmaceutical company that specializes in developing and commercializing novel drug delivery technologies, particularly its ENHANZE platform based on recombinant human hyaluronidase.

  • Congress Asset Management Co. filed the report on March 24, 2026, detailing its holdings as of the end of the fourth quarter of 2025.

The players

Congress Asset Management Co.

An investment management firm that decreased its stake in Halozyme Therapeutics by 9.4% in the fourth quarter of 2025.

Halozyme Therapeutics, Inc.

A biopharmaceutical company focused on developing and commercializing novel drug delivery technologies, including its ENHANZE platform.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Congress Asset Management Co.'s position in Halozyme Therapeutics could signal a shift in market sentiment towards the biopharmaceutical company, though further analysis would be needed to determine the broader implications for the stock and the company's outlook.